Dermatologic Oncology News & Articles

Looking for the latest in oncology clinical literature? You've found the right page. MDLinx Oncology medical editors comb through the top peer-reviewed clinical journals for the articles they think will make a difference to you and your practice. You'll find them organized here by topic including breast, hematologic, thoracic, gastrointestinal and genitourinary cancers. In a matter of minutes, oncologists, oncology nurses, physician assistants and the whole cancer care team can stay current on the literature as it is published.

On this page, you'll also find MDLinx exclusive content, including monthly highlights from our physician editor, D. Scott Cunningham, MD, PhD. We feature clinical pearls as well, from The Smartest Oncologist to oncology topics in The Smartest Pediatrician daily quiz challenges.

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Smartest Doc Challenge
MDLinx
Today Only! We’re helping you prep for your board exams

D Scott Cunningham MD, PhD
Site Editor, MDLinx
Markers of obesity and inflammation in postmenopausal breast cancer

Jill Baker
MDLinx Career Center
NPs and PAs play crucial role amid PCP shortage

MDLinx Reminder
MDLinx
Conference Center Upgraded with New Tools

MDLinx Top Read
MDLinx
Running from that pile of unread journals?

New!	>> Find out who is the Smartest Doc in Oncology!

Articles

Latest (3) Full Text Articles (147) Focus on Pancreas

Ranked, sorted, and summarized by MDLinx editors from the latest literature

Topics:

321 A Phase III Skin Cancer Chemoprevention Study of DFMO: Long-term Follow-up of Skin Cancer Events and Toxicity Cancer Prevention Research, December 7, 2012

322 Clinical and Safety Profile of High-Dose Interleukin-2 Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma Oncology, December 7, 2012

323 Preservation of the deep muscular fascia and locoregional control in melanoma Surgery, December 7, 2012

324 The TWEAK Receptor Fn14 Is a Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment Journal of Investigative Dermatology, December 6, 2012

325 Dermal Equivalents in Oncology: Benefit of One-Stage Procedure Dermatologic Surgery, December 6, 2012

326 Obesity and risk of malignant melanoma: A meta-analysis of cohort and case?control studies European Journal of Cancer, December 5, 2012

327 Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic Melanoma Cancer Research, December 5, 2012 Clinical Article

328 Tumor Recurrence 5 Years after Treatment of Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma Journal of Investigative Dermatology, December 5, 2012 Clinical Article

329 Raf Kinase Inhibitor RKIP Inhibits MDA-9/Syntenin-Mediated Metastasis in Melanoma Cancer Research, December 5, 2012

330 A Novel Evolutionarily Conserved Element Is a General Transcriptional Repressor of p21WAF1/CIP1 Cancer Research, December 5, 2012

331 Cutaneous Digital Papillary Adenocarcinoma: A Clinicopathologic Study of 31 Cases of a Rare Neoplasm With New Observations American Journal of Surgical Pathology , December 5, 2012

332 Analysis of Skin Cancer Treatment and Costs in the United States Medicare Population, 1996-2008 Dermatologic Surgery, December 4, 2012 Clinical Article

333 Familial Melanoma–Associated Mutations in p16 Uncouple its Tumor-Suppressor Functions Journal of Investigative Dermatology, December 4, 2012

334 Augmentation of Therapeutic Responses in Melanoma by Inhibition of IRAK-1,-4 Cancer Research, December 4, 2012

335 Plasma 25-Hydroxyvitamin D and Risk of Non-Melanoma and Melanoma Skin Cancer: A Prospective Cohort Study Journal of Investigative Dermatology, December 4, 2012 Clinical Article
Exclusive Author Commentary

336 Poikilodermatous mycosis fungoides with a CD8+ CD56+ immunophenotype:A case report and literature review Journal of Cutaneous Pathology, December 4, 2012

337 Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma Modern Pathology, December 3, 2012

338 Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis Archives of Dermatological Research, December 3, 2012

339 Cutaneous metastasis as the presenting sign of papillary thyroid carcinoma Journal of Cutaneous Pathology, December 3, 2012

340 Incidence, Risk Factors, and Preventative Management of Skin Cancers in Organ Transplant Recipients: A Review of Single- and Multicenter Retrospective Studies from 2006 to 2010 Dermatologic Surgery, November 30, 2012

50 available pages First Previous 17 18 19 20 21 22 23 24 25 26 Next Last

Clinical Pearls in Oncology

The ZORO study demonstrated that the addition of goserelin to neoadjuvant chemotherapy for early breast cancer in premenopausal women resulted in no change in post-chemotherapy rates of amenorrhea
A little over 50% of tumors in women with ER-positive, node-negative breast cancers will have a RS <18, and current data suggests that these women are UNLIKELY to receive a benefit from adjuvant chemotherapy
In patients with completely resected ER-positive DCIS when the surgical specimen also has LCIS, consider breast MRI screening in addition to mammography due to the lower sensitivity of mammograms for lobular disease

» Test your knowledge. Take the Smartest Doc challenge today!

Highlights in Oncology

VEGFR-1 is a prognostic marker for HCC

As reported in the Journal of Pathology, the expression of vascular endothelial growth factor receptor (VEGFR)-1 is elevated in invasive hepatocellular cancer (HCC) specimens. In a study based on 135 HCC specimens, elevated VEGFR-1 was also associated with worse recurrence-free and overall survival.

Read the article summary

HCC risk increased in patients with AIDS

As reported in Cancer, researchers from the NCI have reported that patients with AIDS have a 4-fold increased risk of HCC compared to the general population. The study findings were based on 615,150 patients with AIDS between 1980 and 2009. The risk for HCC in patients with AIDS was essentially the same during the monotherapy/dual therapy and highly active anti-retroviral therapy eras.

Read the article summary

RAB25 is a prognostic marker for ovarian cancer

As reported in the International Journal of Cancer Research and Treatment, the pre-operative level of RAB25 is a predictor of disease-free survival (HR=18.2) and overall survival (HR=33.6) in patients with ovarian cancer. The study involved 36 and 16 women with ovarian cancer and benign tumors, respectively. The pre-operative cell-free DNA of genes (B2M, RAB25, CLDN4, and ABCF2) were measured and RAB25 was shown to be an independent prognostic factor.

Read the article summary

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Most Popular Oncology Articles

Last month's top read Top Articles of 2012

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncology more

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?

Dermatologic Oncology News & Articles

Articles

Clinical Pearls in Oncology

Highlights in Oncology

VEGFR-1 is a prognostic marker for HCC

HCC risk increased in patients with AIDS

RAB25 is a prognostic marker for ovarian cancer

Most Popular Oncology Articles

Other Topics in Oncology